{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T13:37:07Z","timestamp":1771076227770,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urology.2025.02.018","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T16:48:31Z","timestamp":1739810911000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"199","author":[{"given":"Pu","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3649-9686","authenticated-orcid":false,"given":"Dongxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.02.018_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.11654.x","article-title":"Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)","volume":"111","author":"Cardozo","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2025.02.018_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/nau.10010","article-title":"Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women","volume":"22","author":"Chen","year":"2003","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2025.02.018_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2025.02.018_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000447205","article-title":"Overactive bladder syndrome: evaluation and management","volume":"11","author":"Leron","year":"2018","journal-title":"Curr Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1359105314522084","article-title":"The psychological impact of overactive bladder: a systematic review","volume":"21","author":"Kinsey","year":"2016","journal-title":"J Health Psychol"},{"key":"10.1016\/j.urology.2025.02.018_bib7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age[J]","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.02.018_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU Guideline Amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of Vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder","volume":"59","author":"Edmondson","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.urology.2025.02.018_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib12","article-title":"Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis","volume":"11","author":"Kennelly","year":"2022","journal-title":"Drugs Context"},{"key":"10.1016\/j.urology.2025.02.018_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/luts.12475","article-title":"Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis","volume":"15","author":"He","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2025.02.018_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.urology.2025.02.018_bib15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.urology.2025.02.018_bib16","unstructured":"Higgins J.P.T., Thomas J., Chandler J. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021), Cochrane. \u3008www.training.cochrane.org\/handbook\u3009."},{"key":"10.1016\/j.urology.2025.02.018_bib17","unstructured":"Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.3.0. The Cochrane Collaboration. \u3008www.cochranehandbook.org\u3009."},{"key":"10.1016\/j.urology.2025.02.018_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.urology.2023.02.003","article-title":"Comparison of Mirabegron and Vibegron in women with treatment-naive overactive bladder: a randomized controlled study","volume":"175","author":"Kinjo","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.02.018_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00345-024-04799-4","article-title":"Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial","volume":"42","author":"Naoki","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/luts.12480","article-title":"Mirabegron versus vibegron in previously untreated female patients with overactive bladder: a randomized, single-clinic, open-label trial","volume":"15","author":"Sato","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"10.1016\/j.urology.2025.02.018_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2025.02.018_bib22","first-page":"179","article-title":"Sex differences in the physiology andpharmacology of the lower urinary tract","volume":"6","author":"Patra","year":"2013","journal-title":"Cur lrol"},{"key":"10.1016\/j.urology.2025.02.018_bib23","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib24","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib25","first-page":"2215","article-title":"Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis","volume":"52","author":"Jian","year":"2020","journal-title":"Int Urol"},{"key":"10.1016\/j.urology.2025.02.018_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Realworld persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.urology.2025.02.018_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13318-013-0133-1","article-title":"The effect of mirabegron, a potent and selective \u03b23-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol","volume":"39","author":"Krauwinkel","year":"2014","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1016\/j.urology.2025.02.018_bib28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","article-title":"Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders","volume":"75","author":"Michel","year":"2023","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.urology.2025.02.018_bib29","doi-asserted-by":"crossref","first-page":"100674","DOI":"10.1016\/j.curtheres.2022.100674","article-title":"Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors","volume":"96","author":"Brucker","year":"2022","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.urology.2025.02.018_bib30","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1007\/s12325-021-01902-8","article-title":"Efficacy of Vibegron and Mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison","volume":"38","author":"Kennelly","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2025.02.018_bib31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:18:44Z","timestamp":1746519524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"alternative-id":["S0090429525001773"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.02.018","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}